Equities

GSK plc

GSK:LSE

GSK plc

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)2,198.00
  • Today's Change18.00 / 0.83%
  • Shares traded8.48m
  • 1 Year change48.56%
  • Beta0.7079
Data delayed at least 20 minutes, as of Feb 06 2026 14:54 GMT.
More ▼

Profile data is unavailable for this security.

About the company

GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.

  • Revenue in GBP (TTM)32.67bn
  • Net income in GBP5.72bn
  • Incorporated1999
  • Employees68.63k
  • Location
    GSK plc980 Great West RoadBRENTFORD TW8 9GSUnited KingdomGBR
  • Phone+44 20 8047 5000Fax+44 20 8047 7807
  • Websitehttps://www.gsk.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
UCB SA5.94bn1.16bn45.28bn9.38k45.28bn9.38k
CSL Ltd11.46bn2.21bn45.32bn32.07k45.32bn32.07k
Merck KGaA18.46bn2.57bn46.06bn62.35k46.06bn62.35k
Regeneron Pharmaceuticals Inc10.54bn3.34bn59.53bn15.41k59.53bn15.41k
Chugai Pharmaceutical Co Ltd5.88bn2.03bn71.59bn7.78k71.59bn7.78k
Vertex Pharmaceuticals Inc8.61bn2.70bn85.51bn6.10k85.51bn6.10k
Sanofi SA-86.80bn-86.80bn85.84bn84.59k85.84bn84.59k
GSK plc32.67bn5.72bn88.86bn68.63k88.86bn68.63k
Bristol-Myers Squibb Co35.40bn5.18bn89.01bn34.10k89.01bn34.10k
Novo Nordisk A/S35.91bn11.90bn110.55bn68.79k110.55bn68.79k
Pfizer Inc45.97bn5.69bn110.64bn81.00k110.64bn81.00k
Data as of Feb 06 2026. Currency figures normalised to GSK plc's reporting currency: UK Pound GBX

Institutional shareholders

17.77%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 02 Jan 2026113.47m2.78%
Dodge & Coxas of 20 Feb 202599.38m2.44%
Schroder Investment Management Ltd.as of 02 Jan 202680.25m1.97%
BlackRock Advisors (UK) Ltd.as of 02 Jan 202672.06m1.77%
Wellington Management Co. LLPas of 02 Jan 202671.25m1.75%
BlackRock Fund Advisorsas of 02 Jan 202665.33m1.60%
Norges Bank Investment Managementas of 02 Jan 202665.08m1.60%
Legal & General Investment Management Ltd.as of 02 Jan 202656.18m1.38%
Vanguard Asset Management Ltd.as of 31 Dec 202553.31m1.31%
SSgA Funds Management, Inc.as of 02 Jan 202647.91m1.18%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.